Pharmigene, Inc. (TPEX:7595)

Market Cap	449.14M -29.9%
Revenue (ttm)	199.89M +71.5%
Net Income	-73.00M
EPS	-1.45
Shares Out	50.47M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	248,711
Open	8.20
Previous Close	8.00
Day's Range	8.15 - 8.93
52-Week Range	7.94 - 14.10
Beta	0.03
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About Pharmigene

Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. It offers molecular diagnostics to test adverse drug reactions; and DNA extraction products for gene expression analysis, clinical molecular diagnosis, human identity testing, forensics, and biomedical research applications. The company also provides pharmacogenomics test, drug allergy test, and functional medicine test services. In addition, it distributes various genomics and genetics equipment and reagents; and provides professional co...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1994
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7595

Financial Performance

In 2025, Pharmigene's revenue was 199.89 million, an increase of 71.53% compared to the previous year's 116.53 million. Losses were -73.00 million, -11.91% less than in 2024.